Movers and Shakers Leading Today Market Buzz

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  14 Nov 2025
 

•   AVXL  
   
  +1.39%
•   CDTX  
   
  -0.12%
•   CYCU  
   
  +4.29%
•   GTBP  
   
  +10.11%
•   GWH  
   
  -3.16%

$CDTX Cidara Therapeutics is the headline mover of the day, soaring more than 105 percent after Merck confirmed a 9.2-billion-dollar acquisition that values the company at 221.50 dollars per share, a massive premium to its previous close. Traders had already been positioned for a potential deal based on filings and reports that circulated overnight, and the official announcement triggered a surge in activity with more than 16 million shares traded. Sentiment is extremely bullish, although the stock is now deeply overbought on technical metrics. With the buyout price set, the upside appears capped unless a rival bidder enters the picture.

$CYCU Cycurion extended its rally as traders reacted to strong after-hours action driven by renewed attention to small cap cybersecurity names. Volume exploded far above average as liquidity rotated aggressively into microcap tech. The move also gained momentum from the strong after-hours performance of MLSS, which helped reinforce sector wide interest. CYCU is now trading above 6 dollars, supported mainly by speculative flows and sharp liquidity rather than a major corporate catalyst. Momentum can continue in the short term, but the setup remains highly reactive.

$IVVD Invivyd posted a gain of more than 33 percent amid exceptional premarket activity. The stock landed on multiple most active lists with more than 133 million shares traded, reflecting algorithmic participation, short covering, and a renewed focus on names in the immunology space. There was no major company announcement, but liquidity alone made IVVD highly attractive for traders looking to capture volatility. Even without fresh news, volume driven movement can persist.

$TOI The Oncology Institute delivered a strong catalyst-based rally after posting better than expected third quarter results and raising full year guidance. Revenue growth accelerated, and the market rewarded the improved visibility with a nearly 29 percent jump. Investors have been rotating into healthcare names that show measurable operational improvement, and TOI matched that trend with conviction. Volume surged to nearly four times average, signaling a decisive shift in sentiment grounded in fundamentals.

$GTBP GT Biopharma moved higher by more than 26 percent after releasing third quarter results that reaffirmed development progress. While not a game changing update, traders in speculative biotech have recently been rewarding any steady forward movement. Volume rose to more than double typical levels, and enthusiasm for the immunotherapy theme helped push the stock higher. The move appears driven mostly by sentiment and sector rotation.

$ITRM Iterum Therapeutics led the losers list with a decline of more than 16 percent after reporting weaker than expected earnings results. The company confirmed softer revenue and ongoing EPS pressure across multiple earnings call transcripts. Although Iterum highlighted an extended cash runway into the second quarter of 2026 and noted progress on recent product launches, traders focused on the immediate financial shortfall. Volume nearly tripled as market participants reassessed near term expectations.

$VCIG VCIG fell more than 21 percent and registered as technically oversold. No new company specific developments were released, so the decline appears driven by weak technical structure, low conviction buying, and lingering pressure from earlier sessions. Volume remained below average, which suggests sellers dominated while potential buyers waited for firmer signals before stepping in.

$SOC Soco International dropped almost 29 percent as a combination of sector wide weakness and oversold momentum signals created selling pressure. Energy stocks have struggled to hold bids this month, and SOCs decline fits neatly into that broader trend. Traders previously watching for an RSI based bounce instead saw the stock push lower as the markets defensive tone intensified.

$GWH ESS Tech declined more than 34 percent during a broader pullback in clean energy and long cycle technology names. With traders rotating away from companies that depend on extended revenue timelines, GWH struggled to attract interest. Volume remained well below average, which indicates the move reflected a lack of bidders rather than urgent selling. Sentiment remains fragile without new catalysts.

$AVXL Anavex Life Sciences was the steepest decliner with a fall of nearly 36 percent following a regulatory update on its Alzheimer candidate. The company plans to request re examination after receiving critical feedback from the CHMP committee, which significantly affected expectations for its development timeline. Volume spiked to more than ten times typical levels as confidence weakened sharply and traders reassessed the path forward.

View All Headlines